DBV Technologies S.A. (DBVT): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a French biopharmaceutical company is tackling food allergies with a unique patch technology? DBV Technologies S.A. (DBVT), headquartered in France, is pioneering epicutaneous immunotherapy to develop innovative treatments for food allergies and other immune diseases. Keep reading to discover DBV Technologies' journey, its mission, how its Viaskin patch works, and how the company plans to make money, especially with the potential launch of its Viaskin Peanut patch.

DBV Technologies S.A. (DBVT) History

DBV Technologies S.A. Founding Timeline

Year established

DBV Technologies was established in 2002.

Original location

The company was originally located in Bagneux, France.

Founding team members

The founding team included:

• Dr. Pierre-Henri Benhamou
• Dr. Christophe Dupont
• Pr. Stéphane Eigenmann

Initial capital/funding

Details regarding the initial capital and funding are not readily available in the provided search results. Further research into historical financial records or company announcements from 2002 might provide this information.

DBV Technologies S.A. Evolution Milestones

DBV Technologies S.A. Transformative Moments

• Early Clinical Successes: The initial positive clinical trial results for EPIT® in 2006 were transformative, validating the potential of the technology and attracting further investment.
• Regulatory Setbacks: The FDA's Refusal to File letter in 2020 for Viaskin Peanut was a significant setback. This led to a strategic reassessment and a shift in focus towards new delivery methods and indications.
• Strategic Pivot (2024): The decision to explore new delivery methods and indications beyond peanut allergy represents a transformative moment, potentially opening new avenues for growth and diversifying the company's pipeline.

To gain more insights into the company's financial standing, consider exploring this resource: Breaking Down DBV Technologies S.A. (DBVT) Financial Health: Key Insights for Investors

DBV Technologies S.A. (DBVT) Ownership Structure

DBV Technologies S.A. exhibits a mixed ownership structure, featuring a combination of institutional, retail, and potentially insider holdings which is typical for a publicly traded company.

DBV Technologies S.A. Current Status

DBV Technologies S.A. is a publicly traded company. This means its shares are available for purchase on a stock exchange, allowing both institutional and retail investors to participate in the company's ownership.

DBV Technologies S.A. Ownership Breakdown

The ownership of DBV Technologies S.A. is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders. The following table provides a general overview of the ownership breakdown, but precise percentages may fluctuate.

For a deeper dive into the company's financial standing, consider exploring: Breaking Down DBV Technologies S.A. (DBVT) Financial Health: Key Insights for Investors

DBV Technologies S.A. Leadership

The leadership team of DBV Technologies S.A. is responsible for the strategic direction and operational management of the company. Key aspects of the leadership structure include:

• Chief Executive Officer (CEO): Leads the executive team and is responsible for the overall performance of the company.
• Board of Directors: Oversees the company's management and ensures that the company is acting in the best interests of its shareholders.
• Executive Team: Consists of the CEO and other top executives who manage various functions within the company, such as finance, research and development, and marketing.

The specific individuals holding these positions are subject to change, but information can typically be found on the company's investor relations website or in its annual reports.

DBV Technologies S.A. (DBVT) Mission and Values

DBV Technologies S.A. focuses on developing innovative medical solutions, particularly in the field of allergy treatments, aiming to improve the quality of life for patients with food allergies and other immunological disorders. The company is committed to scientific rigor and patient-centric innovation.

DBV Technologies S.A.'s Core Purpose

Official mission statement

While DBV Technologies S.A. does not have a single, universally publicized official mission statement, their core purpose is evident through their actions and strategic goals:

• To develop and commercialize innovative, safe, and effective therapies for patients with food allergies and other immunological diseases.
• To improve the quality of life for patients by providing convenient and non-invasive treatment options.
• To advance the understanding of food allergies and immunological disorders through scientific research and clinical trials.
• To establish a leading position in the field of allergy immunotherapy by leveraging their innovative EPIT technology.

Vision statement

DBV Technologies S.A.'s vision is to be a leader in the development of innovative therapies for food allergies and other immunological disorders. Evident through their strategic initiatives, the vision includes:

• Pioneering the development of epicutaneous immunotherapy (EPIT) as a safe and effective treatment option for food allergies.
• Expanding the application of EPIT to address a wider range of immunological diseases.
• Establishing strategic partnerships to accelerate the development and commercialization of their products.
• Creating a future where food allergies are effectively managed, allowing patients to live healthier and more fulfilling lives.

Company slogan/tagline

DBV Technologies S.A. does not have a widely recognized public slogan or tagline. However, considering their focus and objectives, a fitting tagline might emphasize innovation and patient care:

• 'Innovating Allergy Solutions, Improving Lives.'
• 'Empowering Patients Through Advanced Immunotherapy.'
• 'The Future of Allergy Treatment, Today.'

For more in-depth information, you can visit: Mission Statement, Vision, & Core Values of DBV Technologies S.A. (DBVT).

DBV Technologies S.A. (DBVT) How It Works

DBV Technologies S.A. focuses on developing and commercializing epicutaneous immunotherapy (EPIT), a proprietary technology platform, to address unmet needs in the treatment of food allergies and other immunological diseases.

DBV Technologies S.A.'s Product/Service Portfolio

DBV Technologies S.A.'s Operational Framework

DBV Technologies operates through a structured framework encompassing research and development, clinical trials, regulatory affairs, and potential commercialization. Key aspects of their operational processes include:

• Research and Development: DBV focuses on advancing its EPIT platform through ongoing research to expand its application to various allergens and immunological conditions.
• Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its Viaskin products. These trials are crucial for obtaining regulatory approvals. For instance, the Phase 3 study of Viaskin Peanut did not meet its primary endpoint.
• Regulatory Affairs: A significant part of DBV's operations involves navigating regulatory pathways in different regions, including the U.S. (FDA) and Europe (EMA), to secure approval for its products. In 2020, the FDA issued a Complete Response Letter (CRL) regarding the Biologic License Application (BLA) for Viaskin Peanut.
• Manufacturing and Supply Chain: DBV establishes manufacturing processes and supply chains to produce and distribute its EPIT products, ensuring product quality and availability.
• Partnerships and Collaborations: Strategic collaborations with other companies and research institutions enhance DBV's capabilities and resources in developing and commercializing its products.

DBV Technologies S.A.'s Strategic Advantages

DBV Technologies' strategic advantages stem from its innovative technology and focused approach to addressing food allergies and immunological diseases:

• Proprietary EPIT Platform: The EPIT platform offers a non-invasive method of delivering antigens through the skin, potentially providing a safer and more convenient alternative to traditional oral immunotherapy.
• Targeted Approach: DBV focuses on specific patient populations with significant unmet needs, such as children with peanut allergies, allowing for a targeted development and commercialization strategy.
• Potential for Disease Modification: EPIT aims to modify the immune response to allergens, potentially leading to long-term desensitization and improved quality of life for patients.
• Intellectual Property: DBV maintains a portfolio of patents and intellectual property rights related to its EPIT platform and product candidates, providing a competitive advantage.

To learn more about DBV Technologies, explore this resource: Exploring DBV Technologies S.A. (DBVT) Investor Profile: Who’s Buying and Why?

DBV Technologies S.A. (DBVT) How It Makes Money

DBV Technologies S.A., a biopharmaceutical company, operates without generating product revenue as of its latest financial reporting. Instead, it sustains its operations through strategic collaborations and financial instruments.

DBV Technologies S.A.'s Revenue Breakdown

As of the fiscal year 2024, DBV Technologies S.A.'s revenue streams are structured differently from typical product-selling companies. The company primarily relies on funding from research collaborations, partnerships, and financial investments, as it currently has no products on the market generating sales revenue.

DBV Technologies S.A.'s Business Economics

DBV Technologies operates in the biotechnology sector, focusing on developing innovative treatments for food allergies. Its business model is heavily research and development-based, characterized by substantial investment in clinical trials and regulatory processes. Key economic aspects include:

• R&D Expenses: A significant portion of the company's expenditure is allocated to research and development, particularly clinical trials for its lead product candidate, Viaskin Peanut.
• Partnerships and Licensing: Revenue potential hinges on establishing partnerships with larger pharmaceutical companies for licensing agreements, which would provide upfront payments, milestone payments, and royalties on future sales.
• Regulatory Milestones: Achieving regulatory approval, particularly from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is critical. Approval significantly impacts the company's valuation and ability to generate revenue.
• Cash Burn Rate: Monitoring the cash burn rate is crucial, as the company relies on external funding to sustain operations until it can generate revenue from product sales or licensing agreements.

DBV Technologies S.A.'s Financial Performance

DBV Technologies' financial performance reflects its stage as a clinical-stage biopharmaceutical company. Key indicators include:

• Cash Reserves: As of the end of 2024, DBV Technologies reported having approximately $100 million in cash and cash equivalents. This figure is vital for sustaining operations and funding ongoing clinical trials.
• Operating Expenses: The company's operating expenses, primarily R&D and administrative costs, totaled around $80 million for the year 2024.
• Net Loss: DBV Technologies typically reports a net loss, reflecting its investment in R&D without offsetting product revenue. The net loss for 2024 was approximately $75 million.
• Stock Performance: The company's stock performance is closely tied to clinical trial results, regulatory updates, and overall market sentiment towards biotechnology companies.

To gain more insights into the company's values, refer to: Mission Statement, Vision, & Core Values of DBV Technologies S.A. (DBVT).

DBV Technologies S.A. (DBVT) Market Position & Future Outlook

DBV Technologies faces a challenging market position, particularly after the FDA's rejection of Viaskin Peanut, impacting its immediate revenue prospects and requiring strategic reassessment. The company's future outlook hinges on successful pipeline development and navigating regulatory pathways, while also managing financial resources carefully.

Competitive Landscape

It is difficult to accurately assess DBV Technologies' precise market share and competitive positioning as of April 2025 due to the dynamic nature of the pharmaceutical industry and the impact of recent regulatory setbacks. However, a general overview can be provided based on available information and industry trends.

Opportunities & Challenges

Industry Position

DBV Technologies' position in the pharmaceutical industry is characterized by:

• A focus on epicutaneous immunotherapy (EPIT), a novel approach to treating allergies through the skin.
• A portfolio of products in development targeting food allergies, including peanut and cow's milk allergy.
• A history of regulatory challenges, particularly with its lead product candidate, Viaskin Peanut.
• A need to differentiate itself from competitors in the allergy therapeutics market through technological innovation and clinical trial success.

To gain more insights into the company's core values, refer to Mission Statement, Vision, & Core Values of DBV Technologies S.A. (DBVT).